The Food and Drug Administration approved the first drug specifically for the treatment of postpartum depression Tuesday.
The drug, which is administered via an intravenous drip, reportedly works within 48 hours, providing near immediate relief to women experiencing symptoms, according to the New York Times.
Postpartum depression has historically been treated with counseling or general antidepressants, which can take weeks to kick in or may not work at all.
The newly-approved drug, brexanolone, will be marketed as Zulresso. The treatment will be offered only as an in-patient option at certified medical centers because it can cause sudden loss of consciousness, according to an F.D.A. press release.